Is ctDNA becoming indispensable in muscle-invasive bladder cancer?
KEYNOTE-B15 at #ESMO2026 reinforces its prognostic value and shows higher ctDNA clearance with EV + pembrolizumab (82.1% vs 66.7%).
The ? is no longer whether ctDNA matters, but how to integrate it in practice.
73 浏览 · 1 赞 · 0 转发 · 0 回复
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：Juan Pablo Rojas Manrique · x.com